This article is part of the network’s archive of useful research information. This article is closed to new comments due to inactivity. We welcome new content which can be done by submitting an article for review or take part in discussions in an open topic or submit a blog post to take your discussions online.
PLOS Neglected Tropical Diseases, 20 September 2019
Jessica Denis, Sarah Attoumani, Patrick Gravier, Bernard Tenebray, Annabelle Garnier, Sébastien Briolant, Franck de Laval, Véronique Chastres, Gilda Grard, Isabelle Leparc-Goffart, Bruno Coutard, Cyril Badaut
Summary
The serological detection of Zika virus (ZIKV) is a challenge, as ZIKV infection generally leads to an immune response with a high level of cross reactivity against related viruses, such as Dengue virus. Although seroneutralization assays are the gold-standard to address specificity, a rapid and cost-effective detection assay with good specificity and sensitivity could be used for first-line screening. We used a large cohort to define a set of human reference sera to validate an ELISA based on a recombinant ZIKV antigen. The assay showed 90% specificity and 92% sensitivity, providing a good basis for the development of diagnostic assays. Characterization of both DENV-EDIII-purified human and murine IgG induced by ZIKV infection or ZEDIII, respectively, confirmed the good specificity of the antigen.
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007747